Ceramide NanoLiposome in Patients With Advanced Solid Tumors
This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.
Cancer|Carcinoma|Solid Tumors|Tumor
DRUG: Ceramide NanoLiposome
Maximum tolerated dose of Ceramide NanoLiposome in patients with advanced solid tumors., 24 months
Recommended phase II dose, 24 months|Incidence of treatment-related adverse events as assessed by CTCAE v4.0, 24 months|Peak plasma concentration (Cmax), 24 months|Time to maximum plasma concentration (Tmax), 24 months|Ceramide NanoLiposome half-life (t1/2), 24 months|Objective response rate per RECIST v1.1, 24 months
This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.